Nature,关于结直肠癌文章汇总!

2022-08-19 消化界 热心肠小伙伴们 热心肠研究院

Nature文章汇总

Nature Reviews(综述):精准饮食干预辅助癌症药物治疗

Nature Reviews Cancer                                    [IF:60.716]

① 肿瘤据其组织来源、基因改变等发生适应性的代谢改变以满足其生存需要;② 饮食为肿瘤提供营养物质,调节肿瘤增殖、生存相关激素水平;③ 饮食干预可能通过限制肿瘤营养、增强药物治疗效果、调控激素水平、改变全身免疫状态等方式帮助肿瘤治疗;④ 热量限制、模拟禁食、生酮饮食、低脂肪饮食、限制特定氨基酸摄入等饮食干预方式有望用于肿瘤治疗;⑤ 针对性的精准饮食干预与药物治疗相结合可能是肿瘤治疗手段的下步发展方向。

Developing dietary interventions as therapy for cancer
05-25, doi: 10.1038/s41568-022-00485-y

【主编评语】饮食是肿瘤的主要营养来源,但饮食干预对癌症治疗的效果缺乏强有力的证据,临床医生很少将其用于癌症治疗。最新发表在Nature Reviews Cancer的综述回顾了多类癌种中癌细胞代谢改变和关键弱点,描述了如何通过饮食疗法(包括能量或大量营养素限制和间歇性禁食疗法)来潜在靶向这些弱点,并讨论了可与药物疗法结合的饮食策略,这可能会为癌症的精确营养开辟一条道路。(@Lexi)

代谢综合征或增加早发性结直肠癌风险

Gastroenterology                                              [IF:22.682]

① 纳入2009-2010年间的9774081名参与者,随访至2019年,共发生8320例早发性结直肠癌及57257例迟发性结直肠癌;② 代谢综合征与早发性结直肠癌及迟发性结直肠癌的风险增加均相关(校正后的HR分别为1.20及1.19);③ 符合1个、2个、3个、4个或5个代谢综合征组成指标(腰围超标、高血糖、高血压、高血清HDL胆固醇、高血清甘油三酯)分别与早发性结直肠癌风险增加7%、13%、25%、27%及50%相关;④ 上述剂量效应关联在远端结肠癌及直肠癌中显著。

Association between Metabolic Syndrome and the Risk of Colorectal Cancer Diagnosed before 50 years According to Tumor Location
05-26, doi: 10.1053/j.gastro.2022.05.032

【主编评语】年轻人的肥胖患病率升高伴随着早发性结直肠癌发病率的增加,尤其是左侧结肠。Gastroenterology上发表的一项最新研究结果,对韩国的近千万人进行10年以上随访后发现,代谢综合征与结直肠癌风险增加相关,且代谢综合征组成指标与早发性结直肠癌(尤其是远端结肠及直肠)的风险呈剂量效应关联。(@aluba)

计算机辅助结肠镜检查可增加腺瘤检出率

Gastroenterology                                              [IF:22.682]

① 1359名40岁以上的受试者随机分为2组,677人接受标准的结肠镜检查、682人接受计算机辅助的结肠镜检查(CADe),标准结肠镜检查及CADe由22名经认证的胃肠病学专家进行;② CADe组的每次结肠镜检出腺瘤数及总腺瘤检出数均显著高于标准组(1.05 vs. 0.83,719 vs. 562),而具有临床意义的组织学切除比例未显著降低;③ 标准组和CADe组的腺瘤检出率分别为43.9%和47.8%,无显著差异。

Computer-Aided Detection Improves Adenomas per Colonoscopy for Screening and Surveillance Colonoscopy: A Randomized Trial
05-25, doi: 10.1053/j.gastro.2022.05.028

【主编评语】Gastroenterology上发表的一项随机对照试验结果,相比于传统的结肠镜检查,计算机辅助下的结肠镜检查可显著增加每次腺瘤检出数及总腺瘤检出数,非显著地增加腺瘤检出率,但不会降低有临床意义的组织学切除比例。(@aluba)

国内团队:利用尿蛋白进行结直肠癌的诊断及转移鉴别

Nature Communications                                     [IF:14.919]

① 收集552名健康对照及结直肠癌患者的657份尿液样本及993份组织样本;② 基于特定尿蛋白特征用于结直肠癌的诊断(CORO1C、ARPC5及RAD23B)或转移鉴别(CORO1C、RAD23B、GSPT2及NDN);③ 结合尿蛋白特征与粪便免疫化学检测(FIT),相比于FIT,在训练集及验证集中可将结直肠癌诊断敏感性分别提升21.2%及43.7%;④ 结合尿蛋白特征与血清癌胚抗原(CEA),可在CEA阴性结直肠癌患者中分别鉴别出51.5%及75.0%的局部淋巴结转移及远端转移。

Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis
05-19, doi: 10.1038/s41467-022-30391-8

【主编评语】中国医学科学院肿瘤医院的赵晓航团队与中国医学科学院基础医学研究所的孙伟团队在Nature Communications上发表的一项最新研究结果,鉴定出了与结直肠癌相关的特定尿蛋白特征:结合尿蛋白特征与粪便免疫化学检测,可显著提升结直肠癌诊断的敏感性;结合尿蛋白特征与血清癌胚抗原,可显著提升结直肠癌转移的检测敏感性。(@aluba)

SPS和SSL的患者及其亲属都需要监测结直肠癌风险

American Journal of Gastroenterology                 [IF:10.864]

① 纳入59名SPS、754名散发性SSL和性1624名正常结肠镜检查患者对照,评估SPS和散发性SSL患者及亲属的患癌风险;② 与对照组比,SPS患者及其一级亲属患CRC风险分别增加10、5倍,SPS患者一级亲属中任何部位腺瘤/癌风险增加2.6倍;③ SSL患者患前列腺癌的风险增加,在SPS及其家庭成员中未观察到其他常见的结肠外癌风险升高;④ SSL和腺瘤性息肉患者无论息肉大小及发育情况,一级亲属、二级亲属和三级亲属的CRC风险增加50%,需更密切的结肠镜监测。

Cancer Risk in Patients With and Relatives of Serrated Polyposis Syndrome and Sporadic Sessile Serrated Lesions
2021-1210, doi: 10.14309/ajg.0000000000001572

【主编评语】American Journal of Gastroenterology近期发表的人群数据分析显示,锯齿状息肉症(SPS)及其一级亲属患结直肠癌(CRC)的风险增加,散发无蒂锯齿状病变(SSL)患者患前列腺癌的风险增加,且SSL和腺瘤性息肉患者的亲属患CRC风险增加,需更密切的结肠镜监测。(@章台柳)

结直肠癌筛查建议提前到45岁

Gastroenterology                                               [IF:22.682]

① 研究对3,928,727例个体结肠镜筛查结果进行分析,其中211010人小于50岁,129,736例(3.3%)没有结直肠癌或晚期腺瘤家族史,代表小于50岁群体的平均筛查风险;② 50-54岁的晚期肿瘤患病率为6.2%,45-49岁的平均患癌风险为5.0% ,建议在45岁开始筛查;③ 所有年龄组中,男性的肿瘤患病率都高于女性;④ 多变量回归分析显示在各个年龄段,白人比黑人、西班牙人和亚洲人患晚期肿瘤的风险更高,这部分是由锯齿状病变引起的。

Age-stratified prevalence and predictors of neoplasia among US adults undergoing screening colonoscopy in a national endoscopy registry
05-25, doi: 10.1053/j.gastro.2022.05.036

【主编评语】Gastroenterology近期发表的文章,对美国内窥镜检查登记的数据进行分析,发现45-49岁人群中晚期肿瘤的患病率较高,建议在45岁开始内窥镜筛查。同时发现在各个年龄段,白人个体患晚期肿瘤的风险高于黑人、西班牙裔和亚裔个体。这些发现可能为腺瘤检测基准和基于风险的筛查策略提供信息。(@章台柳)

Nature子刊:肿瘤微生物组或可预测肿瘤预后和药物反应

Nature Communications                                    [IF:14.919]

① 在肾上腺皮质癌、宫颈鳞状细胞癌、脑低级胶质瘤和皮下黑色素瘤这四种癌症类型中,与单独的临床协变量相比,肿瘤微生物丰度是更好的预后预测指标;② 在更广泛的癌症中,肿瘤基因表达是一个比微生物丰度更有力的预后预测因素;③ 在五种癌症-药物对中,包括多西他赛治疗乳腺浸润癌和肉瘤,及几种治疗胃腺癌的药物,肿瘤微生物丰度比单独的临床协变量更能预测病人的药物反应;④ 结合肿瘤微生物丰度和基因表达特征,可以适度的改善预测性能。

Predicting cancer prognosis and drug response from the tumor microbiome
05-24, doi: 10.1038/s41467-022-30512-3

【主编评语】在一些癌症中,肿瘤基因表达可以预测病人的预后。然而,RNA- seq和全基因组测序数据不仅包含来自宿主肿瘤和正常组织的读数,还包含来自肿瘤微生物组的读数,因此可以用来推断每个肿瘤中的微生物丰度。Nature Communications近期发表的研究表明,肿瘤微生物丰度,单独或与肿瘤基因表达相结合,可以在一定程度上预测癌症预后,及药物反应。未来可以利用现有的测序技术,或开发新的协议,从RNA-seq和全基因组测序实验中获得更多关于预后和药物反应信息。(@NL)

Nature子刊:不同的热点p53突变体,表现不同的癌症表型

Nature Communications                                      [IF:14.919]

① 比较结直肠癌(CRC)中两个常见的TP53热点突变,即p53R273H和p53R175H的影响;② 与R175突变的CRC肿瘤相比,携带R273突变的肿瘤更容易转移,并导致生存率下降;③ 确定了一个由p53R273H突变调节的独特的转录特征,涉及对基因信号通路的激活,更差的患者预后结果, p53R248Q和p53R248突变也存该特点;④ p53R273H突变能选择性地促进CRC细胞快速扩散、迁移、入侵和转移;⑤ p53R273H的转录输出与优先结合R273特征基因的调控元件有关。

Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
05-19, doi: 10.1038/s41467-022-30481-7

【主编评语】在所有结直肠癌(CRC)病例中,约有60%的TP53基因发生了突变,其中TP53突变基因中超过20%的肿瘤在R175或R273位置发生了错义突变。Nature Communications近期发表的研究发现,与R175突变的肿瘤相比,携带R273突变的CRC肿瘤更容易转移性,并导致生存率下降。提示不同的p53突变体可能会给肿瘤带来不一样的特征,最终影响到病人的治疗效果。因此,更好地了解不同的p53突变体的这种不同贡献及其对环境的依赖性,或有助于在未来实现更好的精准医疗。(@NL)

Nature子刊:RNA剪接或是结直肠癌的治疗新靶点

Nature Communications                                     [IF:14.919]

① 肿瘤细胞的可塑性是癌症靶向治疗的主要障碍之一;② 抑癌基因Apc缺陷的结直肠癌细胞中Wnt信号过度激活,导致RNA剪接因子表达和RNA可变剪接失调;③ 筛选发现剪接因子SRSF1参与这一过程,SRSF1单倍缺失削弱肠细胞可塑性,抑制结直肠癌(CRC)的侵袭性;④ SRSF1调控Kras可变剪接产生更多促进细胞增殖的KRAS 4B亚型,增强肿瘤干细胞可塑性;⑤ SRSF1维持人CRC来源类器官的干性,与人CRC肿瘤干细胞标记物表达相关,可作为CRC的潜在治疗靶点。

RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer
05-19, doi: 10.1038/s41467-022-30489-z

【主编评语】Nature Communications近期发表的文章,发现RNA剪接是结直肠癌中肿瘤细胞去分化的关键驱动因素,从而控制肿瘤细胞可塑性,维持肿瘤干性。(@章台柳)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-10-06 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-10-15 56068730

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-09-12 ms4000001980439764

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-08-30 JMR666

    收益颇多

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-08-19 ms9000000626970205

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-08-19 14608a91m05暂无昵称

    受益匪浅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1885969, encodeId=acf718859694b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 06 19:42:18 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093936, encodeId=acd7209393685, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=442c1372878, createdName=56068730, createdTime=Sat Oct 15 16:29:51 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248468, encodeId=cd191248468d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21ea8320024, createdName=ms4000001980439764, createdTime=Mon Sep 12 07:51:28 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242020, encodeId=13401242020ab, content=收益颇多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Tue Aug 30 10:55:52 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239716, encodeId=93751239e1653, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bed65399645, createdName=ms9000000626970205, createdTime=Fri Aug 19 13:02:08 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239678, encodeId=f13412396e83e, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69265107240, createdName=14608a91m05暂无昵称, createdTime=Fri Aug 19 09:42:43 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453740, encodeId=b6a91453e4033, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 15 10:42:18 CST 2022, time=2022-06-15, status=1, ipAttribution=)]

相关资讯

默克在ASCO21上呈报的肿瘤产品阵容数据突显癌症治疗的重大进展

关键性研究的新分析强调BAVENCIO®在晚期尿路上皮癌不同亚组治疗中的独特临床获益

《癌症发现》发表EXALT-1试验结果,显示人工智能功能性精准医疗平台可改善癌症治疗转归

该研究表明首个人工智能功能性精准医疗平台可指导晚期血液系统癌症患者的治疗选择并改善转归

平衡痴呆症患者癌症治疗中个人需求与服务需求

为痴呆症患者提供以人为中心的护理时,护理结局和满意度提高。

武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物

该核准的依据是1/2期试验的结果,该结果显示,缓解有临床意义,中位缓解持续时间(DoR)约1.5年

Nat Nanotech:诱骗癌细胞摄取化疗药物,增强癌症治疗效果

近日,哈佛医学院/麻省总医院的研究团队在 Nature Nanotechnology 期刊上发表了题为:Therapeutically reprogrammed nutrient signalling

Nature子刊:热量限制完胜!减缓肿瘤进展转移,增强免疫能力!

Nat Commun:无论饮食成分如何,每日热量限制比热量循环更有效地限制了肿瘤的生长